Patents by Inventor Erick Co

Erick Co has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120264770
    Abstract: The invention relates to HSP90 inhibiting compounds consisting of the formula: wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Application
    Filed: October 11, 2011
    Publication date: October 18, 2012
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Erick Co, John D. Lawson, Jeffrey A. Stafford
  • Publication number: 20120172321
    Abstract: The invention relates to HSP90 inhibiting compounds consisting of the formula: wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Application
    Filed: March 1, 2012
    Publication date: July 5, 2012
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Young K. Chen, Erick Co, Prasuna Guntupalli, John D. Lawson, Wolfgang Reinhard Ludwig Notz, Jeffrey A. Stafford, Huong-Thu Ton-Nu
  • Patent number: 8071766
    Abstract: The invention relates to HSP90 inhibiting compounds consisting of the formula: wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: December 6, 2011
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Young K. Chen, Erick Co, Prasuna Guntupalli, John D. Lawson, Wolfgang Reinhard Ludwig Notz, Jeffrey A. Stafford, Huong-Thu Ton-Nu
  • Publication number: 20090305998
    Abstract: The invention relates to HSP90 inhibiting compounds consisting of the formula: wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Application
    Filed: January 30, 2009
    Publication date: December 10, 2009
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Young K. Chen, Erick Co, Prasuna Guntupalli, John D. Lawson, Wolfgang Reinhard Ludwig Notz, Jeffrey A. Stafford, Huong-Thu Ton-Nu
  • Publication number: 20070208020
    Abstract: The invention provides compounds and methods for inhibition of kinases, more specifically p70S6 kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.
    Type: Application
    Filed: October 22, 2004
    Publication date: September 6, 2007
    Inventors: Wei Cheng, Erick Co, Moon Kim, Rhett Klein, Donna Le, Amy Suhako, John Nuss, Wei Xu
  • Publication number: 20060211709
    Abstract: Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.
    Type: Application
    Filed: May 2, 2003
    Publication date: September 21, 2006
    Inventors: Chris Buhr, Tae-Gon Baik, Sunghoon Ma, Zerom Tesfai, Longcheng Wang, Erick Co, Sergey Epshteyn, Abigail Kennedy, Baili Chen, Larisa Dubenko, Neel Anand, Tsze Tsang, John Nuss, Csabaj Peto, Kenneth Rice, Mohamed Ibrahim, Xian Shi, James Leahy, Jeff Chen, Lisa Dalrymple, Timothy Forsyth, Tai Huynh, Grace Mann, Larry Mann, Craig Takeuchi
  • Publication number: 20060199820
    Abstract: The present invention provides compounds useful for inhibiting the ADAM-10 protein, with selectivity versus MMP-1. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role.
    Type: Application
    Filed: June 11, 2003
    Publication date: September 7, 2006
    Inventors: Lynne Bannen, Erick Co, Vasu Jammalamadaka, John Nuss, Moon Hwan Kim, Donna Le, Amy Lew, Morrison Mac, Shumeye Mamo, Richard Khoury, Zhaoyang Wen, Wei Xu
  • Publication number: 20060122171
    Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides oxindole derivatives which inhibit, regulate and/or modulate kinase receptor, particularly VEGF receptor 2 (Flk-1/KDR), FGFR1, and PDGFR (alpha and beta), signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.
    Type: Application
    Filed: November 14, 2003
    Publication date: June 8, 2006
    Inventors: Wei Xu, Lynne Canne Bannen, Samuel Brown, Erick Co, John Nuss, Moon Kim, Rhett Klein, Donna Lee, Amy Tsuhako, Morrison Mac, Jason Parks, Zhaoyang Wen, Wei Cheng
  • Publication number: 20050227973
    Abstract: The present invention provides compounds useful for inhibiting the ADAM-10 protein. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role. The invention also provides methods for making bis-aryl ether sulfonyl chorides and ADAM-10 modulators therefrom.
    Type: Application
    Filed: December 13, 2002
    Publication date: October 13, 2005
    Inventors: S. Brown, Lynne Canne-Bannen, Erick Co, Vasu Jammalamadaka, Rickard Khoury, Moon Kim, Donna Le, Amy Tsuhako, Morrison Mac, Shumeye Mamo, John Nuss, Michael Prisbylla, Wei Xu